Physician profile
Phillip E Essay
NPI 1801851175
$63,174.98
in general payments reported to CMS, 2019-2025
39 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,885 · 2020: $4,654 · 2021: $4,868 · 2022: $2,449 · 2023: $22K · 2024: $952 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,250 · Food and Beverage: $4,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,200.00 |
| Travel and Lodging | $11,202.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,250.00 |
| Food and Beverage | $4,665.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $37,372.75 | 2019-2024 | Senza |
| Globus Medical, INC. | $19,993.41 | 2025 | Senza |
| Relievant Medsystems, INC. | $2,139.15 | 2022-2023 | Intracept |
| Abbvie INC. | $990.05 | 2021-2025 | |
| Abbott Laboratories | $449.20 | 2019-2025 | Proclaim, Eterna |
| Lilly USA, LLC | $214.04 | 2021-2025 | Emgality, Reyvow |
| Collegium Pharmaceutical, INC. | $196.75 | 2019-2025 | Belbuca |
| Supernus Pharmaceuticals, INC. | $164.99 | 2019-2020 | |
| Amgen INC. | $152.02 | 2019-2022 | |
| Lundbeck LLC | $134.69 | 2020-2024 | Vyepti |
| Si-Bone, INC. | $134.64 | 2020-2024 | |
| Scilex Pharmaceuticals INC. | $133.01 | 2019-2024 | Ztlido |
| Pfizer INC. | $120.31 | 2019-2024 | |
| Spr Therapeutics, INC | $105.54 | 2022-2023 | Sprint Pns System |
| Forte Bio-Pharma LLC | $86.59 | 2022-2023 | Prolate, Nalocet |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Essay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.